Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Priyanka Sharma, Eve Rodler, William E. Barlow, Julie Gralow, Shannon Leigh Huggins-Puhalla, Carey K. Anders, Lori J. Goldstein, Ursa Abigail Brown-Glaberman, Thu-Tam Huynh, Christopher Scott Szyarto, Andrew K. Godwin, Harsh B Pathak, Elizabeth M. Swisher, Marc R Radke, Kirsten M Timms, Danika L. Lew, Jieling Miao, Lajos Pusztai, Daniel F. Hayes, Gabriel N. Hortobagyi
Institutions: University of Kansas Medical Center, UC Davis Comprehensive Cancer Center, Fred Hutch Cancer Center, Seattle Cancer Care Alliance, UPMC Hillman Cancer Center, Duke University, Duke Cancer Institute, Fox Chase Cancer Center, University of New Mexico, Kaiser Permanente, Kaiser Permanente Anaheim Medical Center, University of Washington Medical Center, Myriad Genetics, Yale University, University of Michigan, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: AbbVie, National Institutes of Health
OpenAlex ID: W3031702570